Navigation Links
Regeneron Announces Presentation at the 2010 Deutsche Bank BioFest
Date:12/6/2010

TARRYTOWN, N.Y., Dec. 6, 2010 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the 2010 Deutsche Bank BioFest on Tuesday, December 14, 2010.  The presentation is scheduled for 8:00 a.m. Eastern Time.  The session may be accessed through the Company's web site, www.regeneron.com, on the Investor Relations page.  An archived version of the presentation will be available after the live webcast through January 13, 2011.

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions and cancer.  Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com. Contact Information:Michael Aberman, M.D.

Peter DworkinInvestor Relations

Corporate Communications914.345.7799

914.345.7800michael.aberman@regeneron.com

peter.dworkin@regeneron.com
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Regenerons Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
2. Regeneron Pharmaceuticals and BioMed Realty Trust Host Ribbon-Cutting Ceremony at the Landmark at Eastview
3. BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals
4. Sequenom Announces Exercise in Full of Underwriters Option to Purchase Additional Shares
5. The Pittsburgh Life Sciences Greenhouse Announces New Chairman of the Board
6. Dendreon Announces MEDCAC Panel Reviewed PROVENGE Evidence
7. AVANIR Pharmaceuticals Announces Proposed Public Offering of Common Stock
8. Syngenta Announces Photo Prize 2010 Winners
9. 3SBio Inc. Announces Unaudited Third Quarter Results
10. Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo
11. Elsevier Announces the SciVerse ScienceDirect eBooks Collection 2011 Frontlist
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... oncology and dermatology biopharmaceutical company, today is providing ... its previously announced rights offering of up to ... stock and Series C Convertible Preferred Stock to ... As previously announced, the rights offering ...
(Date:2/24/2017)... N.J. , Feb. 24, 2017  Driven ... and biotechnology are now the fastest growing categories, ... Specialty Actives in Personal Care: Multi-regional Market ... research and management consulting firm Kline. ... bioprocesses that make them more effective for skin ...
(Date:2/24/2017)... Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading ... financial results for the fourth quarter and fiscal year of ... Total sales in the fourth quarter of ... 13.6% in USD terms to $77.6 million from $68.3 million ... profit increased by 13.3% to $46.8 million from $41.3 million ...
(Date:2/23/2017)... NEW YORK , Feb. 23, 2017 ... a leading digital health company, and Digital ... telemedicine and remote patient monitoring, announce they are ... DN Telehealth maximizes collaboration compatibility ... extending consultations beyond a physical clinical setting to ...
Breaking Biology Technology:
(Date:2/14/2017)... 14, 2017  Wake Forest Baptist Medical Center today ... chief executive officer (CEO). Freischlag joins the medical center ... McConnell , M.D., who last year announced that he ... Center, after leading it since 2008.   ... Wake Forest Baptist,s academic health system, which includes Wake ...
(Date:2/9/2017)... -- The biomass boiler market report by Transparency Market ... globally in terms of revenue (US$ Mn) based on ... biomass boilers has been segmented on the basis of ... market based on feedstock type, has been segmented into ... crops, urban residues, and others. On the basis of ...
(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 /PRNewswire/ ... point. Driven largely by the confluence of organizations, ... users, distaste for knowledge-based systems (password and challenge ... consumer, industrial, and government systems. The market is ... been a demarcation between consumer and enterprise uses ...
Breaking Biology News(10 mins):